SCHEMBL13552858

SCHEMBL13552858

Cc1cnccc1C(=O)Nc1ccc(Cl)c(-c2nccc3ccccc23)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ PTGES O14684 1/20 0.44
▸ CYP11B2 P19099 1/20 0.44
▸ ALB P02768 1/20 0.43
▸ HTR1A P08908 1/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ PDE4A P27815 1/20 0.43
▸ OPRM1 P35372 1/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ HTR2B P41595 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ SHH Q15465 1/20 0.43
▸ USP28 Q96RU2 1/20 0.43
▸ SLC29A1 Q99808 1/20 0.43
▸ SMO Q99835 1/20 0.43
▸ ABCG2 Q9UNQ0 1/20 0.43
▸ CSF1R P07333 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15502733 0.90 PTGES (0.54) TP53MAPTSMN1; SMN2PTGESGRM4
SCHEMBL13554598 0.88 CYP2C9 (0.42) TP53MAPTSMN1; SMN2CYP11B2GRM4
SCHEMBL13044598 0.86 SMN1; SMN2 (0.49) TP53MAPTSMN1; SMN2PTGESALB
SCHEMBL13043449 0.86 KMT2A (0.53) TP53MAPTSMN1; SMN2PTGESALB
SCHEMBL13553152 0.85 TP53 (0.47) TP53MAPTSMN1; SMN2PTGESCYP11B2
SCHEMBL13552720 0.84 GRM4 (0.52) MAPTPTGESSMOGRM4NPC1
SCHEMBL13043661 0.84 USP28 (0.49) MAPTSMN1; SMN2ALBHTR1ASLC6A2
SCHEMBL15502838 0.84 SMO (0.47) TP53MAPTSMN1; SMN2SMOCYP2C9
SCHEMBL13552799 0.83 LMNA (0.56) SMN1; SMN2NPC1HTTRAB9A
SCHEMBL13553142 0.83 CYP2C9 (0.46) ALBHTR1ASLC6A2PDE4AOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9345699-B2 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling NANTBIOSCIENCE, INC. (US) 2016-05-24 — — US disclosed
US-9345699-B2 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling NANTBIOSCIENCE, INC. (US) 2016-05-24 — — US disclosed
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2013-02-21 — — US disclosed
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2013-02-21 — — US disclosed
US-20120270858-A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS SHH, GLI1, SMO TP53 14/4885MAPT 427/4885SMN1; SMN2 1621/4885
US-20120270858-A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling SHH, GLI1, SMO TP53 698/4885MAPT 2831/4885SMN1; SMN2 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback